IgPro20: Clinical Trials

3 completed, 2 terminated, 1 recruiting. 6 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	6	Completed 3, Terminated 2, Recruiting 1

Follow IgPro20: new trials by email Literature Review of IgPro20 trials Research Report on IgPro20

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency	Phase 3	Recruiting	CSL Behring	63	2026-09-15	2026-10-14
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS IgPro20, Placebo - Post-COVID Postural Orthostatic Tachycardia Syndrome	Phase 3	Terminated	CSL Behring	16	2024-08-28	2026-04-13
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) human immunoglobulin G, Placebo - Dermatomyositis	Phase 3	Terminated	CSL Behring	134	2019-10-21	2025-12-09
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Phase 3	Completed	CSL Behring	82	2014-07-30	2018-10-02
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) IgPro20 - Primary Immunodeficiency (PID)	Phase 3	Completed	CSL Behring	40	2008-08-01	2014-04-02
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) IgPro20 - Primary Immune Deficiency	Phase 3	Completed	CSL Behring	21	2008-06-01	2014-04-02

Conditions studied

Primary Immunodeficiency Diseases (2)  ·  Agammaglobulinemia (1)  ·  Burkitt Lymphoma (1)  ·  Dermatomyositis (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Multiple Myeloma (1)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)

Sponsors

CSL Behring (6)

Countries

United States (5)  ·  France (4)  ·  Germany (4)  ·  Spain (4)  ·  Canada (3)  ·  Italy (3)  ·  Poland (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Czechia (2)  ·  Japan (2)  ·  Switzerland (2)  ·  Argentina (1)  ·  Australia (1)  ·  Denmark (1)

Results publications

PMID 24412910

NIH funding

2023 (2), 2008 (1), 2018 (1)